Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $72.2 million.

  • Upstream Bio's Cash & Equivalents rose 11902.39% to $72.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year increase of 11902.39%. This contributed to the annual value of $325.9 million for FY2024, which is 116153.37% up from last year.
  • Upstream Bio's Cash & Equivalents amounted to $72.2 million in Q3 2025, which was up 11902.39% from $45.5 million recorded in Q2 2025.
  • Upstream Bio's Cash & Equivalents' 5-year high stood at $325.9 million during Q4 2024, with a 5-year trough of $25.8 million in Q4 2023.
  • For the 3-year period, Upstream Bio's Cash & Equivalents averaged around $77.8 million, with its median value being $47.3 million (2023).
  • Over the last 5 years, Upstream Bio's Cash & Equivalents had its largest YoY gain of 116153.37% in 2024, and its largest YoY loss of 3036.9% in 2024.
  • Upstream Bio's Cash & Equivalents (Quarter) stood at $25.8 million in 2023, then soared by 1161.53% to $325.9 million in 2024, then plummeted by 77.86% to $72.2 million in 2025.
  • Its last three reported values are $72.2 million in Q3 2025, $45.5 million for Q2 2025, and $71.3 million during Q1 2025.